Orphazyme A/S (OZYMF)
USD 90.0
(0.0%)
USD 90.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -11.26 Million DKK | 71.04% |
| 2022 | -38.91 Million USD | -308.82% |
| 2021 | -9.51 Million DKK | 91.17% |
| 2020 | -107.86 Million DKK | -1444.92% |
| 2019 | -6.98 Million DKK | 98.23% |
| 2018 | -394.7 Million DKK | 37.52% |
| 2017 | -631.73 Million DKK | -4302.64% |
| 2016 | -14.34 Million DKK | 78.83% |
| 2015 | -67.77 Million DKK | 13.02% |
| 2014 | -77.91 Million DKK | -202.81% |
| 2013 | -25.73 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2 Million USD | 0.0% |
| 2023 Q1 | -30.34 Million DKK | 28.55% |
| 2023 Q2 | -30.34 Million USD | 0.0% |
| 2023 Q3 | -11.26 Million DKK | 62.86% |
| 2023 Q4 | -11.26 Million USD | 0.0% |
| 2023 FY | -11.26 Million DKK | 71.04% |
| 2022 Q2 | -6.95 Million DKK | 85.95% |
| 2022 Q4 | -42.46 Million USD | -9.11% |
| 2022 FY | -38.91 Million USD | -308.82% |
| 2022 Q1 | -49.53 Million DKK | 20.48% |
| 2022 Q3 | -38.91 Million DKK | -459.23% |
| 2021 Q1 | -277.64 Million DKK | 57.69% |
| 2021 Q2 | -275.59 Million DKK | 0.74% |
| 2021 Q3 | -64.86 Million DKK | 76.46% |
| 2021 Q4 | -62.28 Million DKK | 3.97% |
| 2021 FY | -9.51 Million DKK | 91.17% |
| 2020 Q1 | -532.69 Million DKK | -1046.06% |
| 2020 FY | -107.86 Million DKK | -1444.92% |
| 2020 Q4 | -656.21 Million DKK | 0.55% |
| 2020 Q2 | -529.5 Million DKK | 0.6% |
| 2020 Q3 | -659.87 Million DKK | -24.62% |
| 2019 Q3 | -49.35 Million DKK | 77.15% |
| 2019 Q4 | -46.48 Million DKK | 5.83% |
| 2019 Q1 | -216.01 Million DKK | 45.27% |
| 2019 Q2 | -216.01 Million DKK | 0.0% |
| 2019 FY | -6.98 Million DKK | 98.23% |
| 2018 Q4 | -394.7 Million DKK | 0.0% |
| 2018 FY | -394.7 Million DKK | 37.52% |
| 2018 Q2 | -513.37 Million DKK | 0.0% |
| 2018 Q1 | -513.37 Million DKK | 18.74% |
| 2018 Q3 | -394.7 Million DKK | 23.11% |
| 2017 Q3 | -631.73 Million DKK | -1780.78% |
| 2017 FY | -631.73 Million DKK | -4302.64% |
| 2017 Q2 | -33.58 Million DKK | 0.0% |
| 2017 Q1 | -33.58 Million DKK | -134.09% |
| 2017 Q4 | -631.73 Million DKK | 0.0% |
| 2016 Q3 | -14.34 Million DKK | 0.0% |
| 2016 Q4 | -14.34 Million DKK | 0.0% |
| 2016 Q1 | 68.01 Million DKK | 0.0% |
| 2016 FY | -14.34 Million DKK | 78.83% |
| 2015 FY | -67.77 Million DKK | 13.02% |
| 2014 FY | -77.91 Million DKK | -202.81% |
| 2013 FY | -25.73 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1574.221% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1028.339% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1218.271% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 126.334% |
| GB Sciences, Inc. | 1.74 Million USD | 744.932% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -27.479% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -121485.958% |
| Skye Bioscience, Inc. | -5.72 Million USD | -96.963% |
| Zenith Capital Corp. | 10.06 Thousand USD | 112073.37% |
| Agentix Corp. | 37.63 Thousand USD | 30046.055% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 299.509% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1684.055% |
| ContraFect Corporation | -6.02 Million USD | -87.006% |
| CSL Limited | 10.52 Billion USD | 100.107% |
| CytoDyn Inc. | 20.26 Million USD | 155.616% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 3232.801% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1910.677% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 125.945% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -55118.542% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1315.398% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1874.179% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -78.745% |
| SQZ Biotechnologies Company | -36.23 Million USD | 68.903% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1409.982% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 171.49% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 602.579% |
| Mesoblast Limited | 55.85 Million USD | 120.174% |
| Marizyme, Inc. | 18.56 Million USD | 160.687% |
| Genus plc | 190.6 Million USD | 105.912% |
| Pharming Group N.V. | 109.8 Million USD | 110.263% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1757.206% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1075.309% |
| IMV Inc. | 7.67 Million USD | 246.913% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 304.82% |
| MultiCell Technologies, Inc. | 90.04 USD | 12515648.645% |
| ONE Bio Corp. | 9.04 Million USD | 224.657% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 187.046% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 136.882% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 663.621% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 187.994% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 8160.571% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 56822.203% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -6031.521% |
| Enzolytics Inc. | 981.65 Thousand USD | 1247.958% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.445% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 76.03% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 259.37% |
| Genscript Biotech Corporation | -1.06 Billion USD | 98.938% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 373.651% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 2904.287% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 572.29% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 6950.081% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -61418.725% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 604.018% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 8469.789% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1435.332% |
| Helix BioMedix, Inc. | -2.57 Million USD | -338.477% |
| EV Biologics, Inc. | 1.36 Million USD | 923.775% |
| Q BioMed Inc. | 4.06 Million USD | 377.561% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 155.578% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 118.612% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 351.99% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 611.766% |
| HST Global, Inc. | 96.79 Thousand USD | 11742.371% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -860129.008% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 5564.632% |
| Halberd Corporation | 144.72 Thousand USD | 7886.707% |
| Resverlogix Corp. | 6.45 Million USD | 274.686% |
| Cell Source, Inc. | 9.23 Million USD | 222.065% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 516.043% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -90.896% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 5722.356% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 617.291% |
| Kadimastem Ltd | -253.1 Thousand USD | -4352.355% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 8386.7% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 5699.392% |
| LadRx Corporation | -2.03 Million USD | -453.36% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1874.179% |
| Affymax, Inc. | -5.59 Million USD | -101.34% |
| Itoco Inc. | 228.3 Thousand USD | 5035.941% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 327.335% |
| Mobile Lads Corp. | 484.23 Thousand USD | 2427.19% |
| International Stem Cell Corporation | 2.59 Million USD | 535.097% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 693.444% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1741631.066% |
| Qrons Inc. | 351.42 Thousand USD | 3306.64% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 246.237% |
| SYBLEU INC | 473.71 Thousand USD | 2478.862% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -4414.462% |
| Rebus Holdings, Inc. | 305 Thousand USD | 3794.754% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 352.837% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 18155.533% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 616.713% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 428.16% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 231.755% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1558.568% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -801.52% |
| Neutra Corp. | 52.18 Thousand USD | 21693.5% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -352.752% |
| PureTech Health plc | -167.19 Million USD | 93.26% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -4501.32% |
| IXICO plc | -4.44 Million USD | -153.544% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 185.249% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 120.545% |
| CSL Limited | 10.52 Billion USD | 100.107% |
| Cellectis S.A. | -43.81 Million USD | 74.283% |